I watched with high interest the webcast from the last ESC congress http://spo.escardio.org/SessionDetails.aspx?id=398931#.UEiARUSHdRA and also read the paper on the NEJM (Pubmed ID 22920912). After a careful analysis of those data I think it is NOT the time to exclude IABP from the treatment of cardiogenic shock; also the trial, although well designed, has some limitation as also some very important details are overlooked.
I'd like to hear your thoughts about it.